The DOI matches its Crossref record.
cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model
Open accessAbstract
Ser-13 and Ser-54 were shown to provide the sole sites for the protein kinase A (PKA)-mediated phosphorylation of the human cAMP-specific phosphodiesterase isoform HSPDE4D3. The ability of PKA to phosphorylate and activate HSPDE4D3 was mimicked by replacing Ser-54 with either of the negatively charged amino acids, aspartate or glutamate, within the consensus motif of RRES54. The PDE4 selective inhibitor rolipram {4-[3-(cyclopentoxy)-4-methoxyphenyl]-2-pyrrolidone} inhibited both PKA-phosphorylated HSPDE4D3 and the Ser-54 → Asp mutant, with an IC50 value that was ∼ 8-fold lower than that seen for the non-PKA-phosphorylated enzyme. Lower IC50 values for inhibition by rolipram were seen for a wide range of non-activated residue 54 mutants, except for those which had side-chains able to serve as hydrogen-bond donors, namely the Ser-54 → Thr, Ser-54 → Tyr and Ser-54 → Cys mutants. The Glu-53 → Ala mutant exhibited an activity comparable with that of the PKA phosphorylated native enzyme and the Ser-54 → Asp mutant but, in contrast to the native enzyme, was insensitive to activation by PKA, despite being more rapidly phosphorylated by this protein kinase. The activated Glu-53 → Ala mutant exhibited a sensitivity to inhibition by rolipram which was unchanged from that of the native enzyme. The double mutant, Arg-51 → Ala/Arg-52 → Ala, showed no change in either enzyme activity or rolipram inhibition from the native enzyme and was incapable of providing a substrate for PKA phosphorylation at Ser-54. No difference in inhibition by dipyridamole was seen for the native enzyme and the Ser-54 → Asp and Ser-54 → Ala mutants. A model is proposed which envisages that phosphorylation by PKA triggers at least two distinct conformational changes in HSPDE4D3; one of these gives rise to enzyme activation and another enhances sensitivity to inhibition by rolipram. Activation of HSPDE4D3 by PKA-mediated phosphorylation is suggested to involve disruption of an ion-pair interaction involving the negatively charged Glu-53. The increase in susceptibility to inhibition by rolipram upon PKA-mediated phosphorylation is suggested to involve the disruption of a hydrogen-bond involving the side-chain hydroxy group of Ser-54.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Overview of PDEs and Their Regulation
Omori, K., & Kotera, J. (2007) · Circulation Research · doi:10.1161/01.res.0000256354.95791.f1 · Cited by 796
HOUSLAY, M. D., & ADAMS, D. R. (2003) · Biochemical Journal · doi:10.1042/bj20021698 · Cited by 763
Self-citationMammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions
Francis, S. H., Blount, M. A., & Corbin, J. D. (2011) · Physiological Reviews · doi:10.1152/physrev.00030.2010 · Cited by 639
Keynote review: Phosphodiesterase-4 as a therapeutic target
Houslay, M. D., Schafer, P., & Zhang, K. Y. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03622-6 · Cited by 635
Self-citationCyclic nucleotide phosphodiesterases: Relating structure and function
Francis, S. H., Turko, I. V., & Corbin, J. D. (2000) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(00)65001-8 · Cited by 564
mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module
Dodge, K. L. (2001) · The EMBO Journal · doi:10.1093/emboj/20.8.1921 · Cited by 507
The Concise Guide to PHARMACOLOGY 2013/14: Enzymes
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12451 · Cited by 425
Burgin, A. B., Magnusson, O. T., Singh, J., Witte, P., Staker, B. L., Bjornsson, J. M., Thorsteinsdottir, M., Hrafnsdottir, S., Hagen, T., Kiselyov, A. S., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1598 · Cited by 397
Physiological Substrates of cAMP-Dependent Protein Kinase
Shabb, J. B. (2001) · Chemical Reviews · doi:10.1021/cr000236l · Cited by 373
AKAP Mediated Signal Transduction
Michel, J. J. C., & Scott, J. D. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.083101.135801 · Cited by 342
Houslay, M. D., Baillie, G. S., & Maurice, D. H. (2007) · Circulation Research · doi:10.1161/01.res.0000261934.56938.38 · Cited by 317
Self-citationYarwood, S. J., Steele, M. R., Scotland, G., Houslay, M. D., & Bolger, G. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.21.14909 · Cited by 306
Self-citationHoffmann, R., Baillie, G. S., MacKenzie, S. J., Yarwood, S. J., & Houslay, M. D. (1999) · The EMBO Journal · doi:10.1093/emboj/18.4.893 · Cited by 270
Self-citationMacKenzie, S. J., Baillie, G. S., McPhee, I., MacKenzie, C., Seamons, R., McSorley, T., Millen, J., Beard, M. B., van Heeke, G., & Houslay, M. D. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704743 · Cited by 260
Self-citationPhosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer's Disease
Gurney, M. E., D'Amato, E. C., & Burgin, A. B. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0309-7 · Cited by 121
Gurney, M. E., Cogram, P., Deacon, R. M., Rex, C., & Tranfaglia, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-15028-x · Cited by 69
MacKenzie, K. F., Wallace, D. A., Hill, E. V., Anthony, D. F., Henderson, D. J. P., Houslay, D. M., Arthur, J. S. C., Baillie, G. S., & Houslay, M. D. (2011) · Biochemical Journal · doi:10.1042/bj20101184 · Cited by 65
Self-citation
Metadata
- Authors
- HOFFMANN, R., WILKINSON, I. R., McCALLUM, J. F., ENGELS, P., & HOUSLAY, M. D.
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 1998-07-01
- Volume
- 333
- Issue
- 1
- Pages
- 139-149
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- OpenAlex
- W2402700043
- Cited by
- 165
- References
- 0
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.